REtinal Markers In Neuroinflammatory Diseases ("REMIND")

Summary

The goal of this observational study, including patients with Multiple Sclerosis, patients with other neuroinflammatory diseases and healthy controls, is to determine the predictive value of retinal markers in predicting disease progression. Participants complete a questionnaire and undergo various non-invasive retinal routine clinical examinations.

Conditions

• Multiple Sclerosis
• Neuroinflammatory Diseases

Interventions

DIAGNOSTIC_TEST

Optical coherence tomography (OCT)

OCT is used to measure: * peripapillary retinal nerve fiber layer (mean thickness in μm) * ganglion cell-inner plexiform layer (volume in mm\^3 and mean thickness in μm) * other retinal layers (inner nuclear layer, outer plexiform layer, outer nerve layer; volumes in mm\^3 and mean thickness in μm). The "scanner laser ophthalmoscopy"-function of the OCT device is used to continuously record the exact location of each participant's fixation point in relation to their fovea and thereby allows the assessment of the fixation instability. In a subgroup of participants, the "angiography"-module of the OCT device is used to image the retinal blood flow and thereby allows to measure the vascular area density of the superficial retinal capillary plexus and deep retinal capillary plexus.

DIAGNOSTIC_TEST

Static retinal vessel analyzer

Static retinal vessel analyzer is used to determine: * central retinal arteriolar diameter equivalents (in μm) * central retinal venular diameter equivalents (in μm) * arteriolar-to-venular diameter ratio

DIAGNOSTIC_TEST

Dynamic retinal vessel analyzer

In a subgroup of participants, the dynamic retinal vessel analyzer is used to determine the arteriolar ficker light-induced dilatation, venular ficker light-induced dilatation, and Arteriolar constriction, measured in % dilatation in comparison to baseline.

DIAGNOSTIC_TEST

Laser speckle flowgraphy system

In a subgroup of participants, the laser speckle flowgraphy system is used to measure the relative ocular blood flow as expressed in arbitary units of Mean Blur Rate.

OTHER

Questionnaire

All study participants will be asked to fill in a questionnaire with various questions regarding existing eye diseases, other diseases (including vascular diseases/risk factors), and daily physical activity that could influence the results of the retinal examinations. Physical activity will be assessed using an adapted form of the standardized Global Physical Activity Questionnaire.

Sponsors & Collaborators

• University of Basel

  collaborator OTHER

• University Hospital, Basel, Switzerland

  lead OTHER

Principal Investigators

• Athina Papadopoulou, PD Dr. med. · University Hospital Basel, Department of Neurology

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2024-01-31

Primary Completion

2028-12-31

Completion

2029-02-28

Countries

• Switzerland

Study Locations